Active Ingredient(s): Belzutifan
FDA Approved: * August 13, 2021
Pharm Company: * MERCK SHARP DOHME
Category: Cancer

Belzutifan, sold under the brand name Welireg, is a medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma.[1][2][3][4][5][6] It is taken by mouth.[1] The most common side effects include decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.[2] Belzutifan is an hy... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Welireg 40 mg Oral Tablet, Film Coated
NDC: 0006-5331
Merck Sharp & Dohme Corp.